ARTA looks into the business registration and renewal process at Antipolo BOSS 15 January 2021 – Following several complaints received from concerned citizens regarding the business registration and renewal process at the Antipolo City, the Anti-Red Tape Authority (ARTA), together with the Bureau of Local Government Development of the Department of Interior and Local Government,.. read more
ARTA inspects Marikina and Makati BOSS, to rank NCR LGUs based on performance
12 January 2021 – As part of its continuing inspections of LGUs’ compliance with the Ease of Doing Business Law during this year’s business renewal period, the Anti-Red Tape Authority (ARTA) looked into the business one stop-shop (BOSS) of Marikina City yesterday and of Makati City this morning. ARTA’s series of inspections are being conducted.. read more
ARTA starts business one-stop shop inspections
7 January 2021– In time for the renewal season of business permits and licenses this year, the Anti-Red Tape Authority (ARTA) conducted on-the-spot inspections of the Business-One Stop Shop (BOSS) of Quezon City and Pasig City earlier today. The said inspection aims to monitor the LGUs’ compliance with the provisions of the Ease of Doing.. read more
ARTA to LGUs: Implement Business One-Stop Shops
1 January 2021 – The Anti-Red Tape Authority (ARTA) is calling on all Local Government Units (LGUs) to fully implement their Business One-Stop Shops (BOSS) for this year’s business registration and business license renewals. Starting this January, ARTA shall be conducting a series of on-the-spot inspections on LGUs in the National Capital Region and other.. read more
ARTA calls on FDA to streamline registration process of vaccines and medical supplies
5 January 2021 – The Anti-Red Tape Authority (ARTA) is calling on the Food and Drug Administration (FDA) to ensure that the process for the Certificate of Product Registration (CPR) for all vaccines and other medical supplies will be streamlined and shall not be subjected to unnecessary processes and requirements. The FDA previously submitted to.. read more